RhinosinusitisNCT07560254
Clinical Outcomes and Patient Satisfaction With Velnez Versus Nasopore in Nasal Surgery
A study testing VELNEZ Nasal Pack and NASOPORE Nasal Pack in people with Rhinosinusitis and Sinusitis, run by Ayu, Inc. at 1 site in Malaysia.
Trial summary
This clinical trial evaluated two absorbable nasal packing materials - VELNEZ and NASOPORE - in adult patients (18-70 years) who underwent nasal surgery, including septoplasty, FESS, or turbinoplasty. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Rhinosinusitis, Sinusitis, Chronic Rhino-sinusitis
- What is being tested?
- VELNEZ Nasal Pack and NASOPORE Nasal Pack
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteMalaysia
- Study dates
- 11 Sep 2024to 20 Jul 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participants eligible for the use of a nasal pack (either VELNEZ or Nasopore) in routine clinical practice after a planned nasal surgery.
- Male and female in the age group of 18 to 70 years. (Both Included)
- Participants or their LAR who can provide informed consent form in writing.
- Participants who allow their study data to be collected at pre-defined follow-up period.
Who cannot join
- Participants who are unable to be treated with VELNEZ, or Nasopore nasal pack in routine clinical practice after a planned surgery.
- Participant's/ legal guardian (LAR) who cannot provide informed Consent written.
- Participant unwilling or unable to comply with the postoperative visits necessary for data collection.
- Participant with an active infection at the surgery site.
- Participant with a history of asthma.
- Pregnant or lactating Females
Show all 11Show fewer
- Participant who are on aspirin or anti-platelet drugs therapy.
- Participant positive for HIV, HCV, VDRL, HBs Ag.
- Participant who is allergic (Hypersensitive) to any of the ingredients of the nasal packs.
- Participant with bleeding disorders.
- Any medical condition that, in the opinion of the investigator, would make the subject unsuitable for inclusion (e.g., a chronic, relapsing or hereditary disease that may interfere with the outcome of the study).
Trial locations and contacts
1 site in 1 country.
Malaysia1 site
Hospital Al-Sultan Abdullah, Universiti Teknologi MARA, Jalan Hospital, UiTM Sungai Buloh Campus
Sungai Buloh, Selangor, 47000
About this study
Official title: A Prospective, Open-Labelled, Single-Center, Two-Arm, Randomized Clinical Study to Compare Patient Satisfaction and Clinical Outcome Associated With Two Nasal Packs (VELNEZ Vs NASOPORE) in Nasal Surgery.
This clinical trial evaluated two absorbable nasal packing materials - VELNEZ and NASOPORE - in adult patients (18-70 years) who underwent nasal surgery, including septoplasty, FESS, or turbinoplasty.
The study addressed two core questions: whether VELNEZ offered superior haemorrhage control and faster biodegradation, and whether it reduced postoperative pain, fibrosis, adhesion, and discomfort compared to NASOPORE.
Participants were randomised to receive either packing material following surgery. They were monitored on the day of surgery for haemostasis and device performance, then followed up with clinical and endoscopic assessments - including pain scoring and adverse event tracking - through Day 90.
Read the detailed description
This study was a prospective, randomised, open-label, single-centre, two-arm parallel clinical investigation conducted in a post-market setting. It was designed to evaluate and compare the clinical performance of two biodegradable nasal packing materials - VELNEZ and NASOPORE - following routine nasal surgical procedures under real-world conditions.
Rationale and background Nasal packing is routinely employed after septoplasty, FESS, and turbinoplasty to achieve haemostasis, support mucosal healing, and prevent postoperative complications including adhesions and septal haematoma. Conventional non-absorbable packing materials, while effective for haemostasis, are associated with significant patient discomfort, pain at removal, mucosal trauma, and risk of delayed healing. Biodegradable alternatives were developed to address these limitations by obviating the need for mechanical removal and providing a more favourable postoperative environment.
Investigational devices VELNEZ is a biodegradable composite nasal packing material comprising gelatin, chitosan, polyvinyl alcohol, and psyllium husk. Following placement, it was designed to fragment and gradually dissolve within the nasal cavity over several days. Its composition was intended to deliver effective haemostasis, physically separate mucosal surfaces to reduce adhesion formation, and support tissue regeneration - all without requiring removal, thereby minimising procedure-related trauma and improving patient tolerability.
NASOPORE is a biosynthetic, biodegradable polyurethane foam with established clinical use. Its hydrophilic properties allowed it to absorb fluids and conform to the contours of the nasal cavity, providing mechanical support and haemostatic function. Degradation occurred through fragmentation over time, though the rate and completeness of dissolution varied across patients.
Study design and randomisation Participants were assigned in a 1:1 ratio to receive either VELNEZ or NASOPORE as postoperative nasal packing immediately following surgery. Randomisation was performed to minimise selection bias. Given the physical and visual differences between the two materials, blinding of investigators and participants was not feasible; the study was therefore conducted in an open-label manner.
Clinical assessments and follow-up
Assessments were conducted perioperatively and at scheduled postoperative visits through the final follow-up at Day 90. The evaluation framework covered the following domains:
Device performance: Ease of placement, conformability to nasal anatomy, and haemostatic effectiveness were assessed perioperatively. Degradation profile was monitored clinically at each follow-up; irrigation or manual intervention was performed where incomplete dissolution was observed.
Mucosal and structural healing: Endoscopic examination of the surgical site was performed at applicable visits to evaluate mucosal condition, presence of oedema, secretions, fibrosis, scar formation, and adhesion development. Any pressure-related discomfort or structural changes were documented.
Patient-reported outcomes: Symptom burden and quality of life were assessed using the Sino-Nasal Outcome Test (SNOT-22), a validated instrument for sinonasal conditions. Pain and tolerability were evaluated using standardised pain assessment scales at defined time points.
Safety monitoring: Adverse events and serious adverse events were recorded throughout the study. Device-related complications - including infection, hypersensitivity reactions, and signs of delayed healing - were specifically monitored. Vital signs, physical examinations, and laboratory evaluations were conducted per routine clinical practice.
Statistical approach Continuous variables were summarised using descriptive statistics and compared between groups using parametric or non-parametric tests, selected based on data distribution. Categorical variables were analysed using Chi-square or Fisher's exact test, as appropriate. All analyses were conducted at a two-sided significance level.
Ethical and regulatory conduct The study was conducted in accordance with Good Clinical Practice (GCP) and the ethical principles of the Declaration of Helsinki. Institutional Ethics Committee approval was obtained prior to initiation. All participants provided written informed consent before enrolment.
- Conditions
- Rhinosinusitis, Sinusitis, Chronic Rhino-sinusitis
- Being tested
- VELNEZ Nasal Pack, NASOPORE Nasal Pack
- Keywords
- VELNEZ, NASOPORE, Nasal Packing, Biodegradable Nasal Pack, Functional Endoscopic Sinus Surgery, Septoplasty, Rhino Sinusitis
- Medical subject headings
- Rhinosinusitis, Sinusitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
VELNEZ Nasal PackDevice
Also called VELNEZ
VELNEZ is a biodegradable composite nasal packing material composed of gelatin, chitosan, polyvinyl alcohol, and psyllium husk. It is designed to fragment and degrade within the nasal cavity after app
NASOPORE Nasal PackDevice
Also called NASOPORE
NASOPORE is a biosynthetic biodegradable polyurethane foam nasal packing material. It absorbs fluids, conforms to the nasal cavity, and gradually fragments over time. The device is used for postoperative bleeding control, support of nasal structures, and facilitation of healing following nasal surgery.
| Study group | Role | What they receive |
|---|---|---|
| Arm 1: VELNEZ Nasal Pack | Experimental | Participants undergoing planned nasal surgery received the VELNEZ biodegradable nasal pack, applied intraoperatively or immediately postoperatively in accordance with standard surgical practice. The device was intended to provide haemostasis, support mucosal healing, and reduce postoperative complication Receives: Device: VELNEZ Nasal Pack |
| Arm 2: NASOPORE Nasal Pack | Active comparator | Participants undergoing planned nasal surgery received the NASOPORE biodegradable nasal pack, applied intraoperatively or immediately postoperatively in accordance with standard surgical practice. The device was intended to provide haemostasis and structural support within the nasal cavity during the healing process. Receives: Device: NASOPORE Nasal Pack |
What is being measured
The primary outcome is the main question the study is designed to answer.
Clinical Success of Nasal Pack
Proportion of participants achieved successful clinical outcome defined as complete degradation of the nasal pack within 7 days without device-related adverse events, along with acceptable levels of fibrosis and scar formation, absence of moderate to severe postoperative pain, and no significant breathing discomfort due to pressure effect
Measured: Up to Day 90 post-surgery
Secondary outcomes (5)
Postoperative Pain Assessment using Visual Analogue Scale (VAS)
Patient-reported pain levels will be assessed using the Visual Analogue Scale (VAS), a 10 cm horizontal line anchored by "no pain" (score = 0) and "worst imaginable pain" (score = 10). The total score ranges from 0 to 10. Higher scores indicate greater pain intensity and worse outcome (lower tolerability of the nasal pack).
Measured: From Day 0 to Day 14 post-nasal surgery
Time to Haemorrhage Control
Time (in minutes) from application of the nasal pack at completion of surgery to achievement of complete haemostasis, as assessed by the operating surgeon
Measured: Day 0 (Intraoperative)
Adhesion Formation (Endoscopic Assessment)
Incidence and severity of nasal adhesions assessed using endoscopic examination during follow-up visits.
Measured: Up to Day 90 post-surgery on post surgery follow up visits
Endoscopic Healing Assessment
Assessment of nasal mucosal healing based on endoscopic findings including mucosal oedema, nasal secretions, and presence of polyps during follow-up visits
Measured: From Day 7 to Day 90 post-surgery
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Number and proportion of participants experiencing adverse events, serious adverse events, or device-related complications during the study period.
Measured: From Day 0 to Day 90 post-surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 May 2026
- Study start11 Sep 2024
- Primary completion11 Apr 2025
- Study completion20 Jul 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for RhinosinusitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The study followed a parallel assignment model in which participants were randomised in a 1:1 ratio to receive either VELNEZ or NASOPORE as postoperative nasal packing. Each participant was assigned to a single treatment arm and remained in that arm throughout the study; no crossover occurred. The allocation sequence was determined using a predefined randomisation schedule to minimise selection bias and ensure balanced distribution across treatment groups. Given the physical differences between the two devices, blinding was not feasible; the study was therefore conducted in an open-label manner, with both investigators and participants aware of the assigned intervention. Both devices were applied intraoperatively or immediately postoperatively as part of routine surgical care. All participants received standard perioperative and postoperative management, with clinical assessments conducted at predefined follow-up time points to evaluate device performance, outcomes, and safety.
- Masking
- None (open label)
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ayu, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Abdul Azim Al-Abrar Ahmad Kailani, Principal investigator, Universiti Teknologi MARA (UiTM), Selangor, MalaysiaMogana S Rajagopal, Study director, UCSI University, Kuala Lumpur, Malaysia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07560254
- Sponsor's protocol ID
- DMPL/CIP-002-2024/CT/VN
- Status last verified
- Apr 2026
- First submitted
- 24 Apr 2026
- Last updated
- 6 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data (IPD) will not be shared due to confidentiality considerations. Aggregated study results will be made available through publications.
Study at a glance
From the registry record, last updated by the sponsor on 6 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Open-Labelled, Single-Center, Two-Arm, Randomized Clinical Study to Compare Patient Satisfaction and Clinical Outcome Associated With Two Nasal Packs (VELNEZ Vs NASOPORE) in Nasal Surgery.
- ClinicalTrials.gov ID
- NCT07560254
- Acronym / sponsor ID
- DMPL/CIP-002-2024/CT/VN
- Conditions
- Rhinosinusitis, Sinusitis, Chronic Rhino-sinusitis
- Keywords
- VELNEZ, NASOPORE, Nasal Packing, Biodegradable Nasal Pack, Functional Endoscopic Sinus Surgery, Septoplasty, Rhino Sinusitis
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- Ayu, Inc.Industry (pharma, biotech, devices)
- Study start
- 11 Sep 2024 (actual)
- Primary completion
- 11 Apr 2025 (actual)
- Study completion
- 20 Jul 2025 (actual)
- First posted
- 1 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This clinical trial evaluated two absorbable nasal packing materials - VELNEZ and NASOPORE - in adult patients (18-70 years) who underwent nasal surgery, including septoplasty, FESS, or turbinoplasty.
The study addressed two core questions: whether VELNEZ offered superior haemorrhage control and faster biodegradation, and whether it reduced postoperative pain, fibrosis, adhesion, and discomfort compared to NASOPORE.
Participants were randomised to receive either packing material following surgery. They were monitored on the day of surgery for haemostasis and device performance, then followed up with clinical and endoscopic assessments - including pain scoring and adverse event tracking - through Day 90.
Detailed description
This study was a prospective, randomised, open-label, single-centre, two-arm parallel clinical investigation conducted in a post-market setting. It was designed to evaluate and compare the clinical performance of two biodegradable nasal packing materials - VELNEZ and NASOPORE - following routine nasal surgical procedures under real-world conditions.
Rationale and background Nasal packing is routinely employed after septoplasty, FESS, and turbinoplasty to achieve haemostasis, support mucosal healing, and prevent postoperative complications including adhesions and septal haematoma. Conventional non-absorbable packing materials, while effective for haemostasis, are associated with significant patient discomfort, pain at removal, mucosal trauma, and risk of delayed healing. Biodegradable alternatives were developed to address these limitations by obviating the need for mechanical removal and providing a more favourable postoperative environment.
Investigational devices VELNEZ is a biodegradable composite nasal packing material comprising gelatin, chitosan, polyvinyl alcohol, and psyllium husk. Following placement, it was designed to fragment and gradually dissolve within the nasal cavity over several days. Its composition was intended to deliver effective haemostasis, physically separate mucosal surfaces to reduce adhesion formation, and support tissue regeneration - all without requiring removal, thereby minimising procedure-related trauma and improving patient tolerability.
NASOPORE is a biosynthetic, biodegradable polyurethane foam with established clinical use. Its hydrophilic properties allowed it to absorb fluids and conform to the contours of the nasal cavity, providing mechanical support and haemostatic function. Degradation occurred through fragmentation over time, though the rate and completeness of dissolution varied across patients.
Study design and randomisation Participants were assigned in a 1:1 ratio to receive either VELNEZ or NASOPORE as postoperative nasal packing immediately following surgery. Randomisation was performed to minimise selection bias. Given the physical and visual differences between the two materials, blinding of investigators and participants was not feasible; the study was therefore conducted in an open-label manner.
Clinical assessments and follow-up
Assessments were conducted perioperatively and at scheduled postoperative visits through the final follow-up at Day 90. The evaluation framework covered the following domains:
Device performance: Ease of placement, conformability to nasal anatomy, and haemostatic effectiveness were assessed perioperatively. Degradation profile was monitored clinically at each follow-up; irrigation or manual intervention was performed where incomplete dissolution was observed.
Mucosal and structural healing: Endoscopic examination of the surgical site was performed at applicable visits to evaluate mucosal condition, presence of oedema, secretions, fibrosis, scar formation, and adhesion development. Any pressure-related discomfort or structural changes were documented.
Patient-reported outcomes: Symptom burden and quality of life were assessed using the Sino-Nasal Outcome Test (SNOT-22), a validated instrument for sinonasal conditions. Pain and tolerability were evaluated using standardised pain assessment scales at defined time points.
Safety monitoring: Adverse events and serious adverse events were recorded throughout the study. Device-related complications - including infection, hypersensitivity reactions, and signs of delayed healing - were specifically monitored. Vital signs, physical examinations, and laboratory evaluations were conducted per routine clinical practice.
Statistical approach Continuous variables were summarised using descriptive statistics and compared between groups using parametric or non-parametric tests, selected based on data distribution. Categorical variables were analysed using Chi-square or Fisher's exact test, as appropriate. All analyses were conducted at a two-sided significance level.
Ethical and regulatory conduct The study was conducted in accordance with Good Clinical Practice (GCP) and the ethical principles of the Declaration of Helsinki. Institutional Ethics Committee approval was obtained prior to initiation. All participants provided written informed consent before enrolment.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- The study followed a parallel assignment model in which participants were randomised in a 1:1 ratio to receive either VELNEZ or NASOPORE as postoperative nasal packing. Each participant was assigned to a single treatment arm and remained in that arm throughout the study; no crossover occurred. The allocation sequence was determined using a predefined randomisation schedule to minimise selection bias and ensure balanced distribution across treatment groups. Given the physical differences between the two devices, blinding was not feasible; the study was therefore conducted in an open-label manner, with both investigators and participants aware of the assigned intervention. Both devices were applied intraoperatively or immediately postoperatively as part of routine surgical care. All participants received standard perioperative and postoperative management, with clinical assessments conducted at predefined follow-up time points to evaluate device performance, outcomes, and safety.
| Arm | Type | Receives |
|---|---|---|
| Arm 1: VELNEZ Nasal Pack | Experimental | Device: VELNEZ Nasal PackParticipants undergoing planned nasal surgery received the VELNEZ biodegradable nasal pack, applied intraoperatively or immediately postoperatively in accordance with standard surgical practice. The device was intended to provide haemostasis, support mucosal healing, and reduce postoperative complication |
| Arm 2: NASOPORE Nasal Pack | Active comparator | Device: NASOPORE Nasal PackParticipants undergoing planned nasal surgery received the NASOPORE biodegradable nasal pack, applied intraoperatively or immediately postoperatively in accordance with standard surgical practice. The device was intended to provide haemostasis and structural support within the nasal cavity during the healing process. |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Participants eligible for the use of a nasal pack (either VELNEZ or Nasopore) in routine clinical practice after a planned nasal surgery.
- Male and female in the age group of 18 to 70 years. (Both Included)
- Participants or their LAR who can provide informed consent form in writing.
- Participants who allow their study data to be collected at pre-defined follow-up period.
Key exclusion criteria (11 listed)
- Participants who are unable to be treated with VELNEZ, or Nasopore nasal pack in routine clinical practice after a planned surgery.
- Participant's/ legal guardian (LAR) who cannot provide informed Consent written.
- Participant unwilling or unable to comply with the postoperative visits necessary for data collection.
- Participant with an active infection at the surgery site.
- Participant with a history of asthma.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| VELNEZ Nasal PackAlso: VELNEZVELNEZ is a biodegradable composite nasal packing material composed of gelatin, chitosan, polyvinyl alcohol, and psyllium husk. It is designed to fragment and degrade within the nasal cavity after app | Device | Arm 1: VELNEZ Nasal Pack |
| NASOPORE Nasal PackAlso: NASOPORENASOPORE is a biosynthetic biodegradable polyurethane foam nasal packing material. It absorbs fluids, conforms to the nasal cavity, and gradually fragments over time. The device is used for postoperative bleeding control, support of nasal structures, and facilitation of healing following nasal surgery. | Device | Arm 2: NASOPORE Nasal Pack |
Primary outcome
Clinical Success of Nasal Pack
Time frame: Up to Day 90 post-surgery
Proportion of participants achieved successful clinical outcome defined as complete degradation of the nasal pack within 7 days without device-related adverse events, along with acceptable levels of fibrosis and scar formation, absence of moderate to severe postoperative pain, and no significant breathing discomfort due to pressure effect
5 secondary outcomes
Postoperative Pain Assessment using Visual Analogue Scale (VAS)
Time frame: From Day 0 to Day 14 post-nasal surgery
Time to Haemorrhage Control
Time frame: Day 0 (Intraoperative)
Adhesion Formation (Endoscopic Assessment)
Time frame: Up to Day 90 post-surgery on post surgery follow up visits
Endoscopic Healing Assessment
Time frame: From Day 7 to Day 90 post-surgery
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: From Day 0 to Day 90 post-surgery
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 May 2026.
- Individual participant dataSharing planned: No. Individual participant data (IPD) will not be shared due to confidentiality considerations. Aggregated study results will be made available through publications.
Related trials for Rhinosinusitis
RecruitingPhase 3
A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Nasal Polyps
RecruitingPhase 3
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
RecruitingPhase 4
Biologics in Chronic Rhinosinusitis With Nasal Polyposis
Chronic Sinusitis, Nasal Polyps
Active, not recruitingPhase 3
A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab
Chronic Rhinosinusitis With Nasal Polyps
Enrolling by invitationObservational study
Firefighter's Longitudinal Airway and Respiratory Exposome/Multiome Study (FLARES)
Anosmia, Chronic Obstructive Pulmonary Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Abdul Azim Al-Abrar Ahmad Kailani principal investigator
Universiti Teknologi MARA (UiTM), Selangor, Malaysia
Mogana S Rajagopal study director
UCSI University, Kuala Lumpur, Malaysia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing VELNEZ Nasal Pack and NASOPORE Nasal Pack in people with Rhinosinusitis and Sinusitis, run by Ayu, Inc. at 1 site in Malaysia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Malaysia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Clinical Success of Nasal Pack (time frame: Up to Day 90 post-surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 May 2026.